You are here

  • Home
  • Archive
  • Volume 65, Issue 4
  • Immunoadsorption and CD20 antibody treatment in a patient with treatment resistant systemic lupus erythematosus and preterminal renal insufficiency

Article Text

Article menu
Download PDFPDF
Letter
Immunoadsorption and CD20 antibody treatment in a patient with treatment resistant systemic lupus erythematosus and preterminal renal insufficiency
  1. J Rech,
  2. A J Hueber,
  3. S Kallert,
  4. C Requadt,
  5. J R Kalden,
  6. H Schulze-Koops
  1. Department of Internal Medicine III, University Of Erlangen-Nuremberg; D-91054 Erlangen; Germany
  1. Correspondence to:
    Dr J Rech
    juergen.rech{at}med3.imed.uni-erlangen.de

https://doi.org/10.1136/ard.2005.043026

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Treatment options in severe progressive systemic lupus erythematosus (SLE) are limited and associated with serious potential side effects, such as cytotoxicity, immunosuppression or metabolic imbalances. As SLE is characterised by quantitative and qualitative abnormalities of B cell functions, we reasoned that a combination of extracorporeal therapy (immunoadsorption)1 with a monoclonal antibody (mAb) to CD20 to deplete the circulating B cell pool2–4 might be beneficial in the treatment of refractory severe SLE.

    A 49 year old white man who was diagnosed for SLE with primary renal, cardiac, and pulmonary disease in 1989, presented in August 2004. The disease was highly active (European Consensus Lupus Activity Measurement (ECLAM) score 5, pancytopenia, raised anti-dsDNA antibodies, markedly …

    View Full Text